News
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,
Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.
Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback